Phase II Study of FOLFIRINOX for Advanced Pancreatic Cancer
What is the purpose of this trial?
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Secondary endpoints include: determine objective response rate according to RECIST; determine overall survival; evaluate toxicity; determine rate of resection in locally advanced unresectable stratum; correlate time to progression, objective response, and overall survival with early changes in glucose metabolism using [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scanning.
- 18 Years and older
- Yale University
- October 2011
- Last Updated:
- January 31, 2012
- Study HIC#:
Clinicaltrials.gov ID: NCT01523457